taladegib

Taladegib is an orally bioavailable small molecule antagonist of the Hedgehog (Hh) pathway protein smoothened (SMO). By inhibiting SMO, taladegib suppresses Hh signaling, which can lead to inhibition of tumor cell proliferation in cancers where this pathway is abnormally activated. The Hh signaling pathway plays a critical role in cellular growth, differentiation, and repair; its constitutive activation is associated with uncontrolled cellular proliferation observed in various cancers. Taladegib has been investigated for use in solid tumors including colon cancer, breast cancer, advanced cancer types such as rhabdomyosarcoma and basal cell carcinoma[1][2][3][7][8]. It is also being studied for idiopathic pulmonary fibrosis (IPF), where it targets myofibroblasts involved in fibrotic tissue remodeling[4][5]. Originally developed by Eli Lilly and Company as LY2940680 and later licensed to Ignyta (now part of Roche), current development for IPF is led by Endeavor BioMedicines[7].

Brand names

taladegib

Other names

taladegib